Bexarotene is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. Bexarotene must not be administered to a pregnant woman. (8.1)
Monitoring data
Negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within one week prior to therapy. Repeat pregnancy test at monthly intervals during therapy
Effective contraception used for 1 month prior to initiation of therapy, during therapy and > 1 month after drug discontinued.